Prescription drugs; price transparency. (HB876)
Introduced By
Sen. Suhas Subramanyam (D-Ashburn) with support from co-patrons Del. Chris Hurst (D-Blacksburg), and Del. Shelly Simonds (D-Newport News)
Progress
✓ |
Introduced |
✗ |
Passed Committee |
☐ |
Passed House |
☐ |
Passed Senate |
☐ |
Signed by Governor |
☐ |
Became Law |
Description
Prescription drug price transparency. Requires every health carrier, pharmacy benefits manager, wholesale drug distributer, and drug manufacturer to report information about prescription drug prices and related information to the Department of Health and requires the Department to make such information available on its website. Read the Bill »
Outcome
Bill Has Failed
History
Date | Action |
---|---|
01/07/2020 | Committee |
01/07/2020 | Prefiled and ordered printed; offered 01/08/20 20104912D |
01/07/2020 | Referred to Committee on Health, Welfare and Institutions |
01/17/2020 | Assigned HWI sub: Health Professions |
01/29/2020 | Impact statement from DPB (HB876) |
01/30/2020 | House committee, floor amendments and substitutes offered |
01/30/2020 | Subcommittee recommends continuing to 2021 |
02/04/2020 | Continued to 2021 in Health, Welfare and Institutions |
02/04/2020 | Continued to 2021 with substitute in Health, Welfare and Institutions |